Atara Biotherapeutics (ATRA) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Leadership and technology differentiation

• First and only approved allogeneic T-cell therapy (EBVALLO/tab-cel) for PTLD, with European approval and U.S. FDA priority review pending for January 2025.

• Platform leverages donor-derived EBV-specific T cells, enabling unique disease targeting and scalable manufacturing.

• Commercial patients are being treated in Europe through a partner, with plans to expand into the U.S.

• ATA3219, an allogeneic EBV CD19 CAR T, is entering clinical trials, aiming for best-in-class status in lymphoma and autoimmune diseases.

ATA3219 program and clinical design

• ATA3219 uses a next-generation CAR (1XX) and a memory phenotype for improved efficacy and safety.

• Maintains EBV-specific TCR for safety and efficacy, with over 600 patients treated on the platform.

• Phase I study is open-label, with four dose levels and two expansion arms, targeting relapsed/refractory Non-Hodgkin lymphoma; initial data expected Q1 2025.

• Preclinical data show similar cytolytic potential to autologous CAR T but with less inflammation, suggesting lower toxicity.

Differentiation in autoimmune disease

• ATA3219 may be administered without lymphodepletion, a key advantage for patients intolerant to chemotherapy.

• Two parallel phase I cohorts in lupus: one with and one without lymphodepletion, with global site expansion to Canada and Australia.

• Preclinical data confirm potent B-cell depletion with lower cytokine release compared to autologous CAR T.

• Enrollment expected to be strong due to product differentiation, protocol design, experienced CRO, and global site selection.